March Biosciences and CTMC Form Strategic Alliance to Propel Innovative Cancer Cell Therapies
Houston, TX – September 11, 2023 – March Biosciences, a startup committed to combating challenging cancers unresponsive to existing immunotherapies, has forged a strategic alliance with CTMC, a joint venture between Resilience + MD Anderson Cancer Center. The partnership is focused on the development of March Biosciences’ lead asset, MB-105, an advanced cellular therapy currently in clinical studies at Baylor College of Medicine for the treatment of relapsed T-cell cancers.
Download the full article: CTMC-March-Bio-Press-Release_Final.Sept11.2023.pdf